[EN] SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME<br/>[FR] COMPOSÉS TRICYCLIQUES CONTENANT DE LA PYRIDINONE SUBSTITUÉE, ET PROCÉDÉS LES UTILISANT
申请人:ARBUTUS BIOPHARMA INC
公开号:WO2018085619A1
公开(公告)日:2018-05-11
The present invention includes substituted pyridinone-containing tricyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection in a patient. In certain embodiments, the compounds and compositions of the invention inhibit and/or reduce HBsAg secretion.
Pd-Catalyzed <i>Ortho</i> C–H Hydroxylation of Benzaldehydes Using a Transient Directing Group
作者:Xiao-Yang Chen、Seyma Ozturk、Erik J. Sorensen
DOI:10.1021/acs.orglett.7b02906
日期:2017.12.1
The direct Pd-catalyzed ortho C–H hydroxylation of benzaldehydes was achieved using 4-chloroanthranilic acid as the transient directing group, 1-fluoro-2,4,6-trimethylpyridnium triflate as the bystanding oxidant, and p-toluenesulfonic acid as the putative oxygen nucleophile. The unusual C–H chlorination and polyfluoroalkoxylation reactions signaled the importance of external nucleophiles to the outcome
IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20150133446A1
公开(公告)日:2015-05-14
The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, R
x
, R
1
, R
2
, R
3
, X
1
, X
2
and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
Substituted pyridinone-containing trycyclic compounds, and methods using same
申请人:ARBUTUS BIOPHARMA CORPORATION
公开号:US10821103B2
公开(公告)日:2020-11-03
The present invention includes substituted pyridinone-containing tricyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection in a patient. In certain embodiments, the compounds and compositions of the invention inhibit and/or reduce HBsAg secretion.